214
Participants
Start Date
June 30, 2010
Primary Completion Date
September 30, 2013
Study Completion Date
December 31, 2014
Gemzar (Gemcitabine)
1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
TH-302
240 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
TH-302
340 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
New York Oncology Hematology, P.C., Hudson
Roswell Park Cancer Institute, Buffalo
Allegheny General Hospital, Pittsburgh
University of Pittsburgh Medical Center, Pittsburgh
Greater Philadelphia Cancer and Hematology Specialists, P.C., Philadelphia
Fairfax Northern Virginia Hematology Oncology, PC, Fairfax
Emerywood Hematology and Oncology, High Point
Alamance Oncology Hematolgy Associates, Burlington
Duke University Medical Center, Durham
Carolina Oncology Specialists, PA, Hickory
Cancer Care of Western North Carolina, PA, Asheville
Institute for Translational Oncology Research (ITOR), Greenville
Atlanta Cancer Care, Atlanta
Ocala Oncology Center, Ocala
Florida Cancer Institute - New Hope, New Port Richey
Martin Memorial Cancer Center, Stuart
Birmingham Hematology and Oncology Associates, LLC, Birmingham
Vanderbilt University Medical Center, Div. of Medical Oncology, Nashville
Hematology and Oncology Associates at BridgePoint, Tupelo
Purchase Cancer Group, Paducah
Signal Point Clinical Research Center, Middletown
Indiana University Melvin and Bren Simon Cancer, Indianapolis
University of Wisconsin, Madison
Virgina Piper Cancer Institute, Minneapolis
Mayo Clinic Rochester, Rochester
Montana Cancer Institute Foundation, Missoula
Loyola University Medical Center, Maywood
Carle Cancer Center, Urbana
Missouri Cancer Associates, Columbia
Ochsner Cancer Institute, New Orleans
Medical Oncology, Baton Rouge
LSU Health Sciences Center - Feist Weiller Cancer Center, Shreveport
Saint Edward Mercy Medical Center, Fort Smith
Texas Oncology-Sherman, Sherman
Texas Oncology-Dallas Presbyterian Hospital, Dallas
University of Texas Southwestern Medical Center at Dallas, Dallas
Texas Oncology- Fort Worth - 12th Avenue, Fort Worth
Texas Oncology-Wichita Falls Texoma Cancer Center, Wichita Falls
Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center, Beaumont
Texas Oncology-Seton Williamson, Round Rock
Rocky Mountain Cancer Centers, Denver
Mayo Clinic Arizona, Scottsdale
Arizona Oncology Associates, PC - HOPE, Tucson
University of Arizona, Tucson
Comprehensive Cancer Centers of Nevada, Las Vegas
UCLA Medical Center, Los Angeles
Disney Family Cancer Center, Burbank
Scripps Clinical Research Services, La Jolla
Sharp Memorial Hospital, San Diego
Los Palos Oncology and Hematology, Salinas
Palo Alto Medical Foundation, Mountain View
California Pacific Medical Center, San Francisco
Kaiser Permanente Northwest Region Oncology Hematology, Portland
Northwest Cancer Specialists, P.C., Portland
Providence Everett Regional Medical Center, Cancer Research Dept., Everett
Columbia Basin Hematology and Oncology0, Kennewick
Hematology Oncology Associates, PC, Stamford
Massachusetts General Hospital, Boston
University of Massachusetts Medical Center, Worcester
Lead Sponsor
Collaborators (1)
PRA Health Sciences
INDUSTRY
ImmunoGenesis
INDUSTRY